ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.

Sponsored by The Sustainable Green Team (OTC: SGTM), featuring Kevin Harrington - the ORIGINAL Shark from Shark Tank

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 29, 2025 / New to The Street, the nation's leading syndicated business television show, announces the premiere of Episode #639 on Saturday March 298, 2025, at 6:30 PM EST as sponsored programming on Bloomberg Television. This episode, hosted by Jane King, features exclusive interviews with four trailblazing companies transforming their industries:

Featured Companies:

BioVie Inc. (NASDAQ: BIVI)
BioVie is a clinical-stage company focused on neurological and neurodegenerative diseases. The company is advancing innovative therapies for Alzheimer's, Parkinson's, and other inflammatory-driven conditions. CEO Cuong Do, former Head of Strategy at Merck and Samsung, brings deep experience in global healthcare innovation. Do believes that "inflammation may be the key to solving Parkinson's, Alzheimer's, and Long COVID," and BioVie's drug candidate bezisterim has shown the ability to modulate inflammation in clinical trials and may improve long-term outcomes for patients.

Roadzen Inc. (NASDAQ: RDZN)
Roadzen is redefining auto insurance using AI and telematics. CEO Rohan Malhotra discusses the company's newly issued patent, C.A.R.D. - Cognitive Assessment of Risk for Drivers, a 360-degree risk analysis system that provides real-time cognitive and behavioral assessments of drivers and links that data back to insurers for dynamic underwriting and claims optimization. Roadzen is a global company with a presence across North America, Europe, and Asia.

Tonix Pharmaceuticals (NASDAQ: TNXP)
A clinical-stage biopharmaceutical company developing a diverse pipeline of treatments targeting CNS disorders, long COVID, and infectious diseases. Tonix continues to drive clinical innovation and regulatory progress with multiple active trials.

eXoZymes, Inc.
A next-generation biotech company harnessing proprietary enzyme technology to drive transformation across biomanufacturing, waste treatment, and sustainable agriculture. Their enzyme innovation platform is designed to power the future of green industry.

Special Sponsorship

This week's episode is proudly sponsored by The Sustainable Green Team (OTC:SGTM), a leader in eco-friendly solutions and regenerative agriculture. The episode features Kevin Harrington, the original Shark from Shark Tank, spotlighting SGTM's innovations and partnership-driven growth.

About New to The Street

New to The Street is a leading business media platform and television series featuring public and private companies, showcasing their innovation and impact. With a weekly reach across Fox Business and Bloomberg Television, over 2.3 million YouTube subscribers, and a strong social media and billboard presence, New to The Street offers guaranteed visibility through earned and sponsored media.

Now in its 16th year, New to The Street continues to be the go-to destination for CEOs and investors looking for "Opportunities To Considerâ„¢."

Don't Miss It

Show #639 airs Friday, March 28, 2025, at 6:30 PM EST on Bloomberg Television.
Replay and full segments will be available at:
www.NewToTheStreet.com
YouTube: New to The Street TV - @NewtoTheStreetTV
Join over 2.3 million loyal subscribers on our YouTube channel and discover the next big opportunity.

Media Contact:
Monica Brennan
Monica@NewToTheStreet.com

SOURCE: New To The Street



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.